文献速递炎症性肠病消化内镜

肠道超声对克罗恩病12个月病程的预测价值:一项前瞻性研究

Predictive Value of Bowel Ultrasound in Crohn's Disease: A 12-Month Prospective Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-04-22

该前瞻性队列纳入225例回结肠型克罗恩病患者,随访12个月,评估基线肠道超声参数与不良病程(需激素和/或换药和/或住院和/或手术)的关联。多变量分析显示,超声评分>3.52、存在至少1种并发症、粪钙卫蛋白≥250 μg/g及男性是不良结局的独立预测因素。肠道超声可预测克罗恩病12个月病程。

要点

  • 基线肠道超声评分>3.52与12个月不良病程独立相关(OR 6.97)。
  • 基线超声发现狭窄、瘘或脓肿者不良结局风险升高(OR 3.90)。
  • 粪钙卫蛋白≥250 μg/g和男性亦为独立预测因素。

核心结论

  • 肠道超声可预测克罗恩病患者12个月内的不良病程。

研究设计与样本

  • 前瞻性队列研究,连续纳入225例回结肠型克罗恩病患者,随访12个月。

主要发现

  • 基线肠道超声评分>3.52预测不良结局的OR为6.97(95%CI 2.87-16.93,P<.001)。
  • 基线超声存在至少1种并发症(狭窄、瘘、脓肿)的OR为3.90(95%CI 1.21-12.53,P=.021)。
  • 基线粪钙卫蛋白≥250 μg/g的OR为5.43(95%CI 2.25-13.11,P<.001)。
  • 男性预测不良结局的OR为2.60(95%CI 1.12-6.02,P=.025)。

关键数值与推荐

  • 不良病程定义为需要激素和/或改变治疗和/或住院和/或手术。
  • 内镜活动定义为简化克罗恩病内镜活动评分>2。
  • 建立基于超声参数的定量肠道超声评分。

临床怎么用

  • 对回结肠型克罗恩病患者,可用基线肠道超声评分、并发症及粪钙卫蛋白分层评估12个月不良病程风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Mucosal healing is associated with better outcomes in Crohn's disease (CD). Colonoscopy is invasive and poorly tolerated. Bowel ultrasound (US) is a noninvasive tool that increasingly is being used for CD assessment. We assessed the predictive role of baseline bowel US findings on disease course in a large prospective cohort of CD patients for 12 months. METHODS: Ileocolonic CD consecutive patients were followed up for 12 months after performing bowel US. The negative course of CD, defined as the need for steroids and/or change of therapy and/or hospitalization and/or the need for surgery, was assessed. We evaluated this composite end point and subsequently considered each individual end point separately. Predictors of negative disease course were analyzed by logistic regression analysis. RESULTS: There were 225 ileal and/or colonic CD consecutive patients included in the study. We analyzed the association between baseline bowel US parameters and endoscopic activity (defined as a Simplified Endoscopic Activity score for CD > 2) to set up a noninvasive quantitative ultrasound-based score (bowel ultrasound score). The multivariable analysis identified the following independent predictors of a worse outcome throughout the 12-month period as follows: bowel ultrasound score greater than 3.52 (odds ratio [OR], 6.97; 95% CI, 2.87-16.93; P < .001), presence of at least 1 disease complication (stricture, fistula, abscess) at baseline bowel US (OR, 3.90; 95% CI, 1.21-12.53; P = .021), fecal calprotectin value of 250 μg/g or greater at baseline (OR, 5.43; 95% CI, 2.25-13.11; P < .001), and male sex (OR, 2.60; 95% CI, 1.12-6.02; P = .025). CONCLUSIONS: Bowel US predicts the 12-month course in CD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Allocca M, Craviotto V, Bonovas S, et al. Predictive Value of Bowel Ultrasound in Crohn's Disease: A 12-Month Prospective Study. Clin Gastroenterol Hepatol. 2021. PMID: 33895360. doi:10.1016/j.cgh.2021.04.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。